Revance Therapeutics Inc RVNC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RVNC is a good fit for your portfolio.
News
-
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
-
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
-
Revance Announces Proposed Public Offering of Common Stock
-
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
-
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
-
Revance to Participate in Upcoming Investor Conferences
-
Revance Therapeutics Gets Permanent J-Code for Daxxify
Trading Information
- Previous Close Price
- $3.80
- Day Range
- $3.76–3.87
- 52-Week Range
- $3.63–37.94
- Bid/Ask
- $3.76 / $3.77
- Market Cap
- $392.89 Mil
- Volume/Avg
- 510,483 / 1.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.37
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 597
- Website
- https://www.revance.com
Comparables
Valuation
|
Metric
|
RVNC
|
SLRN
|
PNT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 11.36 |
Price/Book Value | — | 0.73 | 3.12 |
Price/Sales | 1.37 | — | 5.50 |
Price/Cash Flow | — | — | 13.90 |
Price/Earnings
RVNC
SLRN
PNT
Financial Strength
|
Metric
|
RVNC
|
SLRN
|
PNT
|
|---|---|---|---|
Quick Ratio | 3.16 | 8.53 | 9.01 |
Current Ratio | 3.80 | 8.65 | 9.14 |
Interest Coverage | −16.41 | — | — |
Quick Ratio
RVNC
SLRN
PNT
Profitability
|
Metric
|
RVNC
|
SLRN
|
PNT
|
|---|---|---|---|
Return on Assets (Normalized) | −32.76% | −57.50% | 20.67% |
Return on Equity (Normalized) | — | −88.66% | 23.56% |
Return on Invested Capital (Normalized) | −43.48% | −96.26% | 23.38% |
Return on Assets
RVNC
SLRN
PNT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gqttvcqkx | Lkjr | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pjqxfdmz | Knkbm | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fvmwpsgj | Qnzvh | $98.1 Bil | |
MRNA
| Moderna Inc | Wfvvrbyc | Qgws | $39.1 Bil | |
ARGX
| argenx SE ADR | Jflrygw | Zpfwd | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Glsrfzmrp | Npqfd | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zhvrpscs | Ttlydds | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bsvpkbgl | Glsmyz | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Glvwyqnyrg | Qtzbq | $12.5 Bil | |
INCY
| Incyte Corp | Fzgchgp | Tmkqzsf | $11.9 Bil |